{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-24-000017","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.342341+00:00","generated_at":"2026-06-05T03:04:54.556683+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zymeworks reports FY 2023 net loss of $118.7M; zanidatamab BLA initiated; cash runway into 2027","bullets":["Revenue $76.0M vs $412.5M in 2022, reflecting non-recurring Jazz upfront; net loss of $118.7M vs net income $124.3M.","Cash, cash equivalents and marketable securities $456.3M as of Dec 31; with milestone payments, runway into 2H 2027.","Rolling BLA for zanidatamab in second-line biliary tract cancers started by Jazz; expected completion 1H 2024.","Jazz initiated Phase 3 confirmatory trial for zanidatamab as first-line BTC; BeiGene expects NMPA BLA filing 2H 2024.","Targeting two IND submissions in 2024 (ZW191, ZW171); ZW49 Phase 2 deprioritized pending collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-24-000017","json":"https://secwatch.observer/filing/0001937653-24-000017.json","markdown":"https://secwatch.observer/filing/0001937653-24-000017.md","text":"https://secwatch.observer/filing/0001937653-24-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765324000017/0001937653-24-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765324000017/zyme-20240306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:04:54.556683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28a4afe241a83acce04896cc3151c55de8deb9e5","claim":"Zymeworks Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000193765324000017/0001937653-24-000017-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}